Overview A Two-year Open-label Extension Study of Ganaxolone in Patients With Drug-resistant Partial-onset Seizures Status: Terminated Trial end date: 2016-12-01 Target enrollment: Participant gender: Summary A follow-on, two-year open-label extension study of ganaxolone as add-on therapy in adult patients with drug-resistant partial-onset seizures Phase: Phase 3 Details Lead Sponsor: Marinus PharmaceuticalsTreatments: GanaxolonePregnanolone